5 Oxytocin antagonists in preterm labour and delivery

Bailliere's Clinical Obstetrics and Gynaecology

Volumn 7, Issue 3, 1993, Pages 577-600

  Melin, Per ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ARGIPRESSIN; ATOSIBAN; L 366948; OXYTOCIN; OXYTOCIN ANTAGONIST; OXYTOCIN RECEPTOR; PROSTAGLANDIN; UNCLASSIFIED DRUG; UTERUS SPASMOLYTIC AGENT; VASOPRESSIN;

DIARRHEA; DRUG BINDING SITE; DRUG BIOAVAILABILITY; DRUG HALF LIFE; DRUG POTENCY; DYSMENORRHEA; FEMALE; GESTATIONAL AGE; HUMAN; INTRANASAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; NAUSEA; PLACENTAL TRANSFER; PREMATURE LABOR; RECEPTOR DENSITY; REVIEW; TISSUE DISTRIBUTION; UTERUS BLOOD FLOW; UTERUS CONTRACTION; VOMITING;

ANIMAL; ARGIPRESSIN; CLINICAL TRIALS; DELIVERY, OBSTETRIC; DRUG EVALUATION, PRECLINICAL; FEMALE; HUMAN; LABOR, PREMATURE; OXYTOCIN; PREGNANCY; RECEPTORS, OXYTOCIN; TOCOLYTIC AGENTS;

EID: 0027248152     PISSN: 09503552     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0950-3552(05)80449-3     Document Type: Article

References (96)

1. Can primary dysmenorrhea be alleviated by a vasopressen antagonist?
2. Vasopressin response and terbutaline inhibition of the uterus
3. Primary dysmenorrhoea and vasopressin
4. Vasopressin effects on isolated non-pregnant myometrium and uterine arteries and their inhibition by deamino-ethyl-lysine-vasopressin and deamino-ethyl-oxytocin
5. Vasotocin analogues which competitively inhibit vasopressin stimulated uterine activity in healthy women
6. Inhibition of uterine contractions of premature labour with an oxytocin analogue. Results from a pilot study
7. 2α-induced abortion
8. Oxytocin receptor blockade: a new principle in the treatment of preterm labor?
9. Correlation between myometrial receptor affinity, lipophilicity and antagonistic potency of oxytocin analogues in rat
10. 2α metabolite levels at cerclage may predict preterm delivery
11. Oxytocin receptor in human fetal membranes at term and during labor
12. The response of the human uterus to oxytocin throughout pregnancy
13. 2+-transporting microsomes derived from uterine sarcoplasmic reticulum
14. A new look at uterine muscle contraction
15. Preterm labour
16. Myometrial oxytocin receptors and prostaglandin in the parturition process in the rat
17. Comparison of the pharmacologic properties of oxytocin and its highly potent analogue, desamino-oxytocin
18. Antioxytocic and antiprostaglandin-releasing effects of oxytocin antagonists in pregnant rats and pregnant human myometrial strips
19. Effects of inactivation of oxytocin receptor and inhibition of prostaglandin synthesis on uterine oxytocin receptor and gap junction formation and labor in the rat
20. Fetal and maternal oxytocin in human parturition
21. Release of oxytocin and vasopressin by the human foetus during labour
22. Synthesis of oxytocin in amnion, chorion and decidua may influence the timing of human parturition
23. Antagonism of oxytocin in rats and pregnant rhesus monkeys by the novel cyclic hexapeptides, L-366, 682 and L-366, 948
24. Ontogeny of the ductus arteriosus response to prostaglandins and inhibitors of their synthesis
25. Preventing preterm birth
26. Profile of an oxytocin antagonist, RWJ 22164, for treatment of preterm labor in laboratory models of uterine contractility
27. An apparent stress-induced release of arginine vasopressin by human neonates
28. SK & F 101926 is antidiuretic in man (abstract)
29. The sequence of amino acids in oxytocin, with a proposal for the structure of oxytocin
30. 9OVT: a selective oxytocin receptor ligand
31. The action of desamino-oxytocin on the human pregnant uterus
32. 2α, indomethacin, oxytocin and an oxytocin antagonist in rats
33. Orally active nonpeptide oxytocin antagonists
34. Human placental and bovine corpora luteal oxytocin
35. Ethanol for prevention of preterm birth
36. Endocrinology of human parturition: a review
37. Oxytocin receptors and human parturition: a dual role for oxytocin in the initiation of labor
38. 2α in preterm labor and the effect of ethanol and ritodrine
39. Oxytocin receptors in the human uterus during pregnancy and parturition
40. Oxytocin antagonist (dTVT) and oxytocin receptors in myometrium and decidua
41. Oxytocin secretion and human parturition: pulse frequency and duration increase during spontaneous labor in women
42. 2α receptors in human myometria and amnion-decidua complex during pregnancy and labor
43. Appearance of gap junctions in the myometrium of women during labor
44. The effect of the oxytocin antagonist Atosiban on preterm uterine activity in the human
45. (In Russian) Serum oxytocin and oxytocinase activities in women during pregnancy
46. Oxytocin and vasopressin: distinct receptors in myometrium
47. Cystin-aminopeptidase und Oxytocin im Plasma schwangerer mit vorzeitiger Wehentätigkeit
48. 8]vasotocin, an oxytocin antagonist, in animal models of uterine contractility and preterm labor: a new tocolytic agent
49. Uterine blood flow and myometrial activity at menstruation, and the action of vasopressin and a synthetic antagonist
50. Bicyclization of a weak oxytocin agonist produces a highly potent oxytocin antagonist
51. 2
52. Comparison of plasma oxytocin and catecholamine concentrations with uterine activity in pregnant Rhesus monkeys
53. 8]oxytocin on spontaneous nocturnal myometrial contractions
54. Oxytocin and the initiation of human parturition. I. Prostaglandin release during induction of labor by oxytocin
55. Vasopressin receptors in human pregnant myometrium and decidua: interactions with oxytocin and vasopressin agonists and antagonists
56. Oxytocin and prostaglandin interactions in pregnancy and at parturition
57. The role of oxytocin: present concepts
58. Assessment of uterine activity in ambulatory patients at high risk of preterm labor and delivery
59. Structure and expression of a human oxytocin receptor
60. Synthesis of 2-ρ-methoxyphenylalanine oxytocin (O-Methyl-oxytocin) and some observations on its pharmacological behaviour
61. Analogs with inhibitory properties
62. Analogues of neurohypophysial hormones containing a D-amino acid in position 2
63. Expression of the oxytocin gene in rat placenta
64. Oxytocin gene expression in rat uterus
65. Mechanism of action of the oxytocin antagonist 1-deamino-2-D-Tyr-(OEt)-4-Thr-8-Orn-oxytocin
66. Pharmacokinetics in the human of a new synthetic vasopressin and oxytocin uterine antagonist
67. Myosin light chain phosphorylation in human myometrial smooth muscle cells
68. Human myometrium during pregnancy contains and responds to V1 vasopressin receptors as well as oxytocin receptors
69. Discovery, development, and some uses of vasopressin and oxytocin antagonists
70. Carboxy terminus of vasopressin required for activity but not binding
71. 1-receptor) responses to vasopressin
72. Antagonism of oxytocin analogues on the human uterus and in animal models
73. Inhibitory effect of O-alkylated analogues of oxytocin and vasopressin on human and rat myometrial activity
74. Uterotonic oxytocin and vasopressin antagonists with minimal structure modifications
75. Synthetic antagonists of the myometrial response to vasopressin and oxytocin
76. Effects of vasopressin on the human non-pregnant uterus: studies with analogues of different vasopressor potencies
77. Oxytocin activates the inositolphospholipid-protein kinase-C system and stimulates prostaglandin production in human amnion cells
78. Amniotic oxytocin and vasopressin in relation to human fetal development and labour
79. A structurally unique, potent, and selective oxytocin antagonist derived from Streptomyces silvensis
80. Identification of an orally-active, nonpeptidyl oxytocin antagonist
81. Structural requirements of the oxytocin receptor in rat uterus
82. Binding of four oxytocin analogues to myometrial oxytocin and arginine-vasopressin binding sites in pregnant women
83. Quantitative comparison between oxytocin and four related neurohypophyseal peptides on the human uterus in situ
84. Presence of oxytocin and arginine vasopressin in human ovary, oviduct, and follicular fluid
85. A role for phosphoinositide hydrolysis in human uterine smooth muscle during parturition
86. 9OVT
87. Vasopressin and Prostaglandins in Premenstrual Pain and Primary Dysmenorrhea
88. Administration of antidiuretic peptide (DDAVP) by way of suction de-epithelialised skin
89. Uterine contractility and oxytocin sensitivity in preterm, term and postterm pregnancy
90. Direct measurement of intracellular free calcium in cultured human puerperal myometrial cells stimulated by oxytocin: effects of extracellular calcium and calcium channel blockers
91. Labelling of vasopressin and oxytocin receptors from the human uterus
92. Plasma oxytocin during the first and second stages of spontaneous human labour
93. 2 in single cultured human myometrial cells
94. The effect of the oxytocin antagonists, CAP 476 and F 327, on calcium mobilisation in single cultured human myometrial cells
95. Newborn oxytocin antagonist (Atosiban) levels during maternal infusion
96. Inhibition of oxytocin-induced uterine contractions by an oxytocin antagonist in the pregnant baboon